GRCL
Gracell Biotechnologies Inc
Chart
Stats
Earnings
News
Splits
Dividends
Earnings
| Actual EPS |
|---|
| Consensus EPS |
| Estimated EPS |
| Number of Estimates |
| EPS Surprise |
Stats
Summary
gracell biotechnologies inc. is a global clinical-stage biopharmaceutical company dedicated to discovering and developing breakthrough cell therapies. leveraging its pioneering fastcar and truucar technology platforms, gracell is developing a rich clinical-stage pipeline of multiple autologous and allogeneic product candidates with the potential to overcome major industry challenges that persist with conventional car-t therapies, including lengthy manufacturing time, suboptimal production quality, high therapy cost and lack of effective car-t therapies for solid tumors.
Market Cap: 991 Million
Primary Exchange: NASDAQ
Website: gracellbio.com
Shares Outstanding: 96.7 Million
Float: 0
Dividend: 0.0 (0.0%)
Beta: 1.8121078586812776
Sector: Manufacturing
Industry: Pharmaceutical Preparation Manufacturing
Ethical Flags
Longest drawdown: 989 trading days
From: 2021-02-05 To: 2024-02-21
Lowest Point:
| Ex-Date | Payment Date | Record Date | Declared Date | Amount | Flag | Dividend Type | Qualified | Indicated |
|---|
| Ex-Date | Declared Date | Record Date | Payment Date | Ratio | To Factor | For Factor |
|---|